CTLA4 and cancer: This is a multicenter study to evaluate the safety of an anti-CTLA-4 human monoclonal antibody (AGEN1884) and to estimate the maximum tolerated dose in subjects with advanced or refractory cancer (Clinicaltrials.gov ID: NCT02694822).